Faubert, B., Solmonson, A. & DeBerardinis, R. J. Metabolic reprogramming and cancer progression. Science 368, 152–163 (2020).
Martinez-Reyes, I. & Chandel, N. S. Cancer metabolism: looking forward. Nat. Rev. Cancer 21, 669–680 (2021).
Heiden, M. G. V., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009).
Schiliro, C. & Firestein, B. L. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells 10, 1056–1097 (2021).
Koundouros, N. & Poulogiannis, G. Reprogramming of fatty acid metabolism in cancer. Br. J. Cancer 122, 4–22 (2020).
Eniafe, J. & Jiang, S. The functional roles of TCA cycle metabolites in cancer. Oncogene 40, 3351–3363 (2021).
Nakhle, J., Rodriguez, A. M. & Vignais, M. L. Multifaceted roles of mitochondrial components and metabolites in metabolic diseases and cancer. Int. J. Mol. Sci. 21, 4405–4436 (2020).
Abdel-Wahab, A. F., Mahmoud, W. & Al-Harizy, R. M. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol. Res. 150, 104511 (2019).
Di Cosimo, S. et al. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today 39, 157–174 (2003).
Qi, H. et al. Shikonin induced apoptosis mediated by endoplasmic reticulum stress in colorectal cancer cells. J. Cancer 13, 243–252 (2022).
Dowsett, M. et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386, 1341–1352 (2015).
Ma, C. X., Reinert, T., Chmielewska, I. & Ellis, M. J. Mechanisms of aromatase inhibitor resistance. Nat. Rev. Cancer 15, 261–275 (2015).
Ruijtenberg, S. & van den Heuvel, S. Coordinating cell proliferation and differentiation: antagonism between cell cycle regulators and cell type-specific gene expression. Cell Cycle 15, 196–212 (2016).
Gaude, E. & Frezza, C. Tissue-specific and convergent metabolic transformation of cancer correlates with metastatic potential and patient survival. Nat. Commun. 7, 13041 (2016).
Garrett, M. et al. Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. Cancer Metab. 6, 4 (2018).
Suzuki, H. et al. Metabolic alteration in hepatocellular carcinoma: mechanism of lipid accumulation in well-differentiated hepatocellular carcinoma. Can. J. Gastroenterol. Hepatol. 2021, 8813410 (2021).
Ma, R. et al. Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma. Nat. Commun. 4, 2508 (2013).
Soballe, P. W. & Herlyn, M. Cellular pathways leading to melanoma differentiation—therapeutic implications. Melanoma Res. 4, 213–223 (1994).
Lei, M. J., Dong, Y., Sun, C. X. & Zhang, X. H. Resveratrol inhibits proliferation, promotes differentiation and melanogenesis in HT-144 melanoma cells through inhibition of MEK/ERK kinase pathway. Microb. Pathog. 111, 410–413 (2017).
Chaabane, F., Pinon, A., Simon, A., Ghedira, K. & Chekir-Ghedira, L. Phytochemical potential of Daphne gnidium in inhibiting growth of melanoma cells and enhancing melanogenesis of B16-F0 melanoma. Cell Biochem. Funct. 31, 460–467 (2013).
Sung, J. Y. & Cheong, J. H. New immunometabolic strategy based on cell type-specific metabolic reprogramming in the tumor immune microenvironment. Cells 11, 768 (2022).
Elia, I., Schmieder, R., Christen, S. & Fendt, S. M. Organ-specific cancer metabolism and its potential for therapy. Handb. Exp. Pharmacol. 233, 321–353 (2016).
Costello, L. C. & Franklin, R. B. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 35, 285–296 (1998).
Franklin, R. B. & Costello, L. C. Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch. Biochem. Biophys. 463, 211–217 (2007).
Goode, D. R., Totten, R. K., Heeres, J. T. & Hergenrothert, P. J. Identification of promiscuous small molecule activators in high-throughput enzyme activation screens. J. Med. Chem. 51, 2346–2349 (2008).
Williams, K. P. & Scott, J. E. Enzyme assay design for high-throughput screening. Methods Mol. Biol. 565, 107–126 (2009).
Werle, M. & Bernkop-Schnurch, A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30, 351–367 (2006).
Casero, R. A., Stewart, T. M. & Pegg, A. E. Polyamine metabolism and cancer: treatments, challenges and opportunities. Nat. Rev. Cancer 18, 681–695 (2018).
Frezza, C. Histidine metabolism boosts cancer therapy. Nature 559, 484–485 (2018).
Pal, P., Hales, K., Petrik, J. & Hales, D. B. Pro-apoptotic and anti-angiogenic actions of 2-methoxyestradiol and docosahexaenoic acid, the biologically derived active compounds from flaxseed diet, in preventing ovarian cancer. J. Ovarian Res. 12, 49–65 (2019).
Tapsell, L. C., Neale, E. P., Satija, A. & Hu, F. B. Foods, nutrients, and dietary patterns: interconnections and implications for dietary guidelines. Adv. Nutr. 7, 445–454 (2016).
Fanzo, J. et al. Nutrients, foods, diets, people: promoting healthy eating. Curr. Dev. Nutr. 4, nzaa069 (2020).
Zhuang, C. et al. Small molecule-drug conjugates: a novel strategy for cancer-targeted treatment. Eur. J. Med. Chem. 163, 883–895 (2019).
Donaldson, M. S. Nutrition and cancer: a review of the evidence for an anti-cancer diet. Nutr. J. 3, 19 (2004).
De Cicco, P. et al. Nutrition and breast cancer: a literature review on prevention, treatment and recurrence. Nutrients 11, 1514 (2019).
Kim, M. et al. Thermohydrogel containing melanin for photothermal cancer therapy. Macromol. Biosci. 17, 1600371 (2017).
Zhao, X. et al. Melanin-inspired design: preparing sustainable photothermal materials from lignin for energy generation. ACS Appl. Mater. Interfaces 13, 7600–7607 (2021).
Wang, K. et al. Melanin-perovskite composites for photothermal conversion. Adv. Energy Mater. 9, 1901753 (2019).
Lunt, S. Y. & Vander Heiden, M. G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27, 441–464 (2011).
Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891–899 (2004).
Saeedi, M., Khezri, K., Zakaryaei, A. S. & Mohammadamini, H. A comprehensive review of the therapeutic potential of alpha-arbutin. Phytother. Res. 35, 4136–4154 (2021).
Zolghadri, S. et al. A comprehensive review on tyrosinase inhibitors. J. Enzym. Inhib. Med. Chem. 34, 279–309 (2019).
Liu, J. L. et al. Spectroscopy and molecular docking analysis reveal structural specificity of flavonoids in the inhibition of alpha-glucosidase activity. Int. J. Biol. Macromol. 152, 981–989 (2020).
Prakash, J. et al. Tumor-targeted intracellular delivery of anticancer drugs through the mannose-6-phosphate/insulin-like growth factor II receptor. Int. J. Cancer 126, 1966–1981 (2010).
Sarna, M., Krzykawska-Serda, M., Jakubowska, M., Zadlo, A. & Urbanska, K. Melanin presence inhibits melanoma cell spread in mice in a unique mechanical fashion. Sci. Rep. 9, 9280 (2019).
Halaban, R. et al. Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. Proc. Natl Acad. Sci. USA 94, 6210–6215 (1997).
Wellbrock, C. & Arozarena, I. Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. Pigment Cell Melanoma Res. 28, 390–406 (2015).
Zhao, X., Fiske, B., Kawakami, A., Li, J. & Fisher, D. E. Regulation of MITF stability by the USP13 deubiquitinase. Nat. Commun. 2, 414 (2011).
Wu, M. et al. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 14, 301–312 (2000).
Gabra, M. B. I. et al. Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth. Nat. Commun. 11, 3326 (2020).
Gonzalez, P. S. et al. Mannose impairs tumour growth and enhances chemotherapy. Nature 563, 719 (2018).
Allen, T. M. & Cullis, P. R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65, 36–48 (2013).
Wu, M. X. & Yang, Y. W. Metal–organic framework (MOF)-based drug/cargo delivery and cancer therapy. Adv. Mater. 29, 1606134 (2017).
Zahorowska, B., Crowe, P. J. & Yang, J. L. Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. J. Cancer Res. Clin. Oncol. 135, 1137–1148 (2009).
Wang, C. et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 574, 268–272 (2019).
Marullo, R. et al. The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastases. Sci. Adv. 7, eabg1964 (2021).
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s41565-024-01690-6
